FR2823225B1 - Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant - Google Patents

Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant

Info

Publication number
FR2823225B1
FR2823225B1 FR0104601A FR0104601A FR2823225B1 FR 2823225 B1 FR2823225 B1 FR 2823225B1 FR 0104601 A FR0104601 A FR 0104601A FR 0104601 A FR0104601 A FR 0104601A FR 2823225 B1 FR2823225 B1 FR 2823225B1
Authority
FR
France
Prior art keywords
rxr
hepatitis
activity
ppar
heterodimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0104601A
Other languages
English (en)
Other versions
FR2823225A1 (fr
Inventor
Pierre Desreumaux
Sebatien Dharancy
Johann Auwerx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0104601A priority Critical patent/FR2823225B1/fr
Priority to AU2002302685A priority patent/AU2002302685A1/en
Priority to US10/474,218 priority patent/US20040171689A1/en
Priority to EP02730347A priority patent/EP1372697A2/fr
Priority to PCT/FR2002/001185 priority patent/WO2002080956A2/fr
Publication of FR2823225A1 publication Critical patent/FR2823225A1/fr
Application granted granted Critical
Publication of FR2823225B1 publication Critical patent/FR2823225B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR0104601A 2001-04-04 2001-04-04 Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant Expired - Fee Related FR2823225B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0104601A FR2823225B1 (fr) 2001-04-04 2001-04-04 Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant
AU2002302685A AU2002302685A1 (en) 2001-04-04 2002-04-04 Use of compounds modulating rxr-ppar heterodimer activity as medicine for treating hepatitis c
US10/474,218 US20040171689A1 (en) 2001-04-04 2002-04-04 Screening method using solid supports modified with self-assembled monolayers
EP02730347A EP1372697A2 (fr) 2001-04-04 2002-04-04 Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a tittre de medicament pour le traitement de l'hepatite c
PCT/FR2002/001185 WO2002080956A2 (fr) 2001-04-04 2002-04-04 Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0104601A FR2823225B1 (fr) 2001-04-04 2001-04-04 Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant

Publications (2)

Publication Number Publication Date
FR2823225A1 FR2823225A1 (fr) 2002-10-11
FR2823225B1 true FR2823225B1 (fr) 2004-09-17

Family

ID=8861952

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0104601A Expired - Fee Related FR2823225B1 (fr) 2001-04-04 2001-04-04 Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant

Country Status (5)

Country Link
US (1) US20040171689A1 (fr)
EP (1) EP1372697A2 (fr)
AU (1) AU2002302685A1 (fr)
FR (1) FR2823225B1 (fr)
WO (1) WO2002080956A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
ITFI20030058A1 (it) * 2003-03-06 2004-09-07 Univ Firenze Formulazioni farmaceutiche contenenti tiazolidinedioni
FR2854078B1 (fr) * 2003-04-28 2008-01-11 Univ Toulouse Procede de fabrication d'une composition therapeutique immuno-stimulante.
GB0327050D0 (en) * 2003-11-20 2003-12-24 Angeletti P Ist Richerche Bio Therapeutic methods compositions and uses
EP1886685A1 (fr) * 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
KR101475630B1 (ko) * 2013-05-31 2014-12-22 동국대학교 산학협력단 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물
CN105521498A (zh) * 2014-10-21 2016-04-27 宁波美丽人生医药生物科技发展有限公司 Rxr在制备用于治疗感染水泡型口炎病毒的药物中的用途
CN105586434A (zh) * 2014-10-21 2016-05-18 宁波美丽人生医药生物科技发展有限公司 Rxr在筛选用于治疗感染水泡型口炎病毒易感的药物中的用途
CN109432431B (zh) * 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
JP7029818B2 (ja) * 2019-11-18 2022-03-04 株式会社カスケード資源研究所 リグニン抽出物を有効成分とする薬剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
AU7074496A (en) * 1995-09-18 1997-04-09 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
WO2001025226A1 (fr) * 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Derives de dithiolane

Also Published As

Publication number Publication date
EP1372697A2 (fr) 2004-01-02
US20040171689A1 (en) 2004-09-02
WO2002080956A2 (fr) 2002-10-17
WO2002080956A3 (fr) 2003-04-10
AU2002302685A1 (en) 2002-10-21
FR2823225A1 (fr) 2002-10-11

Similar Documents

Publication Publication Date Title
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
DK1223980T3 (da) Anvendelse af CSF-1-inhibitorer
RU94045155A (ru) Способы ингибирования болезни альцгеймера
DE69840510D1 (de) Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung
HK1005425A1 (en) Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis
FR2823225B1 (fr) Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant
DK1106178T3 (da) Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose
EA199900633A1 (ru) Способы терапевтического введения анти-cd40l соединений
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
FR2725990B1 (fr) Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
MD940152A (ro) Compoziţie farmaceutică pentru tratarea infecţiilor şi bolilor, provocate de virusul hepatitei V (HBV)
HUP9700661A2 (hu) Alfa1-adrenoreceptor antagonisták felhasználása rák megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
ES2125846T3 (es) Nuevas indicaciones para el empleo de inductores de parainmunidad multipotentes a partir de virus de viruela o virus de paraviruela atenuados, no inmunogenos, como medicamento.
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DE69902999D1 (de) Glucocorticoide zur behandlung von glomerulonephitis
ATE155343T1 (de) Verwendung von 2-(4-(-chlorophenyl)cyclohexyl>-3- hydroxy-1,4-naphtoquinon zur behandlung von krebs
BE899867A (fr) Composition antihyperlipidemie a base de diltiazem.
HUP0003885A2 (hu) Készítmény pangásos szívelégtelenség kezelésére
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
FR2691064B3 (fr) Nouveau medicament pour le traitement de l'arythmie.
DK0561927T3 (da) Farmaceutiske præparater til behandling af maligne B-celle-affektioner
FR2758325B1 (fr) Composes tetracycliques aromatiques de type retinoide leur procede de preparation et leur utilisation pour la fabrication de compositions pharmaceutiques et cosmetiques

Legal Events

Date Code Title Description
AU Other action affecting the ownership or exploitation of an industrial property right
TQ Partial transmission of property
ST Notification of lapse

Effective date: 20081231